

Freedom of Information Act 2000 – Request Reference FoI/23/658
Haematological Cancer

NB: All of the following requests are relating to the treatment of adults (16 years +) only.

The information we request is from your most recent data.

1, Which haematological cancers are treated at your health board?

All haematological cancers are treated at Cardiff and Vale University Health Board (the UHB).

2, How many blood cancer patients are under the care of your health board?

The requestor has confirmed that 'under the care of' refers to anyone who has received a diagnosis and has not been discharged.

In completing a search for the information requested, the UHB has confirmed that this information is not centrally recorded or collated. To retrieve the information requested would require a manual search through individual patient records and the UHB considers that this would exceed the limit set within Regulations for responding to a request. The UHB has therefore relied upon the section 12 exemption of the Freedom of Information Act 2000 ('Exemption where cost of compliance exceeds appropriate limit') and is refusing your request.

The UHB has estimated that to complete the work needed to respond to this request would exceed the time limit as set within Regulations to respond to a Freedom of Information Act request. Under the Act there is an allowance of two and a half days, or 18 hours, to comply with a request and the cost limit set within the Fees Regulations for this amount of work (18 hours) is £450 for the UHB. The Fees Regulations specify that the cost of complying with a request must be calculated at the rate of £25 per hour.

However, in accordance with our duty to provide advice and assistance under section 16 of the Act, the UHB is able to provide the below table. This reflects the number of open suspected and confirmed haematology pathways as at 8 February 2024, where patients have not yet had a first definitive treatment or are yet to have been determined to not have cancer. This includes patients referred from other health boards for specialist advice or treatment. Please note that this is SCP data.

	Diagnosis date recorded	No diagnosis date recorded	Grand Total
Haematological	3	12	15

3, Total number of haematological Clinical Nurse Specialists are in the health board?

6.0 WTE CNS and 1.0 WTE Advanced Nurse Practitioner, excluding the BMT/CAR-T team.

4, Total number of leukaemia specific CNSs are in the health board?

2.0 WTE myeloid CNSs.

- **If you do have leukaemia specific CNSs in the health board, how many leukaemia patients are there per leukaemia CNS's?**

This information is not held.

- **Do have myeloid and lymphoid specific CNSs and if so, how many of each?**

2.0 WTE myeloid, 2.0 WTE lymphoma and 2.0 WTE myeloma.

5, Are haematological/ blood cancer CNSs required to undertake normal ward duties?

The CNS will follow the patient's journey and will need to maintain their clinical skills by undertaking a range of duties relevant to their patient cohort. The CNS team also mentor junior staff on the Haematology Ward but are supernumerary to the ward staff nurses. The senior nursing team will be reviewing the patient pathway to ensure this is seamless due to the increasing complexity of patients.

6, Have you measured patient access to CNSs within the health board? If so, what was the outcome?

This information is not held.

7, Do you have, or plan to have any funding in place for training more haematology or blood cancer specific CNSs?

The Haematology, Immunology and Metabolic Medicine Directorate is always reviewing workforce. There is currently a workforce review that will potentially have significant impact being undertaken. This exercise will take time and needs to go through the correct process. The Directorate is committed to the ongoing education and training of all staff, including the CNS workforce.